Zobrazeno 1 - 10
of 1 705
pro vyhledávání: '"Pharmacoeconomic"'
Autor:
Mary Gamal, Amal Samir Sedrak, Gihan Hamdy Elsisi, Ahmed Elagamy, Ahmed Seyam, Mariam Eldebeiky, Randa Eldessoki
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Vol 7, Iss 4, Pp 216-223 (2024)
Introduction To improve resource allocation within our healthcare system, the Egyptian Authority for Unified Procurement, Medical Supply and the Management of Medical Technology (UPA) and Universal Health Insurance Authority (UHIA) established a join
Externí odkaz:
https://doaj.org/article/63ff6070c3004107a9e421dc87b44661
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 4387-4399 (2024)
Ling-ling Zhu,1 Yan-hong Wang,2 Jian-hua Feng,3 Quan Zhou2 1VIP Geriatric Ward, Division of Nursing, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People’s Republic of China; 2Department of Ph
Externí odkaz:
https://doaj.org/article/a7096f39cfa5484b8aaf930489726c2d
Autor:
Sergey V. Nedogoda, Marina V. Zhuravleva, Sergey N. Tereshchenko, Alla S. Salasyuk, Igor V. Zhirov, Irina N. Barykina, Viktoria O. Lutova, Ekaterina A. Popova
Publikováno v:
Терапевтический архив, Vol 96, Iss 8, Pp 771-779 (2024)
Aim. To evaluate the clinical and economic effectiveness of dapagliflozin in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction (HFrEF) in the Russian Federation in various subgroups of standard therapy for CHF.
Externí odkaz:
https://doaj.org/article/3fd97e36a00640bfba4c78ac473e450d
Autor:
A. R. Kasimova, A. S. Kolbin
Publikováno v:
Фармакоэкономика, Vol 17, Iss 2, Pp 163-171 (2024)
Objective: pharmacoeconomic analysis of the feasibility of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in the pediatric population in comparison with other medicines belonging t
Externí odkaz:
https://doaj.org/article/81cd785f0afb4406ad1cef51dd4f5be3
Autor:
A. S. Kolbin, A. R. Kasimova
Publikováno v:
Фармакоэкономика, Vol 17, Iss 2, Pp 182-190 (2024)
Objective: to perform pharmacoeconomic analysis of the feasibility of using topical bacterial lysate in the form of nasal spray (IRS®19) for the treatment and prevention of upper respiratory tract infections in pediatric population in comparison wit
Externí odkaz:
https://doaj.org/article/896992118f554131a5ad3c8148fc4d81
Autor:
Rongqi Li, Yuhan Zeng, Yizhang Chen, Zhongjiang Ye, Chuang Chen, Jianhui Yang, Jing Fu, Tao Zhou, Danna Jiang, Sunting Qin, Haige Ye, Ziye Zhou, Xiuhua Zhang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundLenalidomide is a thalidomide analog that has immunomodulatory and anti-angiogenic properties. The ECOC-ACRIN E1412 Phase II trial demonstrated that lenalidomide, when combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and
Externí odkaz:
https://doaj.org/article/37e16bff17cc4d8e966904dfaf57143b
Publikováno v:
Biotechnology & Biotechnological Equipment, Vol 38, Iss 1 (2024)
The healthcare structure in Bosnia and Herzegovina is decentralized, thus facing patients with unequal access to healthcare services especially for medicines. We attempted to develop a tool for assessment of the stakeholders’ opinion, and with the
Externí odkaz:
https://doaj.org/article/cc6501b15b0c45038867c7f924927f4a
Autor:
Laila Carolina Abu Esba, Hani Alharbi
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Vol 7, Iss 2, Pp 59-62 (2024)
Introduction Lomitapide is approved for lowering low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemia, which is a rare genetic disorder. The evidence regarding its safety and efficacy from a small clinical trial req
Externí odkaz:
https://doaj.org/article/d20f0eecccb34897977d7008440c86ee
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 21, Iss 1, Pp 1-5 (2023)
Abstract The use of multiple cost-effectiveness thresholds in pharmacoeconomic evaluation is a hotly debated topic in the international academic community. This study analyzed and discussed thresholds in the context of pharmacoeconomic evaluation and
Externí odkaz:
https://doaj.org/article/cef180059a964e3f8d4b416638f0318c